Psoriasiform exfoliative erythroderma induced by golimumab

Golimumab Exfoliative dermatitis Erythroderma Spondylitis
DOI: 10.1111/ced.12402 Publication Date: 2014-08-22T15:35:40Z
ABSTRACT
Golimumab is a fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by with anti-TNF drugs well documented, but to our knowledge, development clinical features psoriasiform exfoliative erythroderma during golimumab has not been previously described.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (10)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....